Home | Metabolism | Phenylketonuria (PKU) | Publications | Publication: Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers

Publication: Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers

This research article in Molecular Genetics and Metabolism Reports, reports results from a Phase 1 clinical study of CNSA-001 (sepiapterin), an agent being investigated for potential treatment of BH₄ deficiencies and phenylketonuria (PKU)

Results from a randomized, double-blind, dose-ranging, Phase 1 clinical trial of 83 healthy subjects who were administered CNSA-001 or placebo are presented and discussed
The pharmacokinetic profile, including plasma levels of sepiapterin and BH₄ following administration of CNSA-001 is reported here, along with adverse events associated with treatment

Smith N, Longo N, Levert K, et al. Mol Genet Metab Rep. 2019;126(4):406–412

Sepiapterin is an investigational drug currently in development for PKU.

Once registered, you will be provided the DOI and PubMed links for this publication.

Register now to unlock the content

Already registered?
If not, register below

Registration

Firstname *

Surname *

Hospital *

Work email *

Specialty *

Country *

This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:

*

I confirm that I am a licensed healthcare professional and would like to access this Website

*

I understand that PTC will process my personal data, including contact details, for the purposes of providing me access to this Website

I want PTC to provide, by email, updates about new content available to view on MEDhub
PTC will delete immediately the information provided if we cannot confirm you are healthcare professional.
Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data.
For any enquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at: Dataprivacy@ptcbio.com.

You can unsubscribe from updates at any time when receiving an email from PTC.

Publication: Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers

Authenticating...

COMING SOON